Blueshift Asset Management LLC Acquires Shares of 4,284 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Blueshift Asset Management LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, Holdings Channel.com reports. The firm bought 4,284 shares of the company’s stock, valued at approximately $494,000.

Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares during the last quarter. Bank of New York Mellon Corp grew its position in Neurocrine Biosciences by 1.4% during the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock valued at $128,639,000 after buying an additional 13,069 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Neurocrine Biosciences by 4.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock worth $94,478,000 after buying an additional 37,098 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after acquiring an additional 203,934 shares during the period. 92.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NBIX has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Jefferies Financial Group boosted their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Trading Down 1.0 %

Shares of NASDAQ NBIX opened at $126.59 on Thursday. The business has a 50-day moving average of $118.97 and a 200-day moving average of $131.71. The firm has a market capitalization of $12.82 billion, a price-to-earnings ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $110.81 and a 12 month high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.